| Hormonal contraception and risk of endometrial cancer: a systematic review. | |
| | |
MedLine Citation:
|
PMID: 20870686 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
More than 15 case-control studies and at least four large cohort studies demonstrated a decrease in the risk of endometrial cancer of about 50% for ever use of combined oral contraceptives (COCs). In most of these studies, this protective effect persisted for more than 10-15-20 years after cessation of the COC. An increasing protective effect with longer duration of COC use has been found in most studies. The beneficial effect was independent of the composition of COC, i.e. dosage and type of progestogen, combined with ethinyl estradiol 30-50 μg/day. COCs with higher progestogen potency seem to be somewhat more effective. Nonhormonal uterine devices have also been found to be strongly protective; however, data on oral or injectable progestogen-only preparations (POPs) including the levonorgestrel-releasing intrauterine system (LNG-IUS) are still rare, but also suggest similar protective action. COCs, POPs, as well as LNG-IUS can effectively reduce endometrial hyperplasia but should only be used in exceptional cases in patients with or after endometrial cancer. In contrast to nonhormonal IUS, systemic side effects cannot be excluded with LNG-IUS, but they are certainly rare, as the main effect has decreased the endometrial estrogen response because of the high endometrial tissue levels of LNG. |
| | |
Authors:
|
Alfred O Mueck; Harald Seeger; Thomas Rabe |
Related Documents
:
|
19509566 - Lymphadenectomy for low-risk endometrial cancer based on preoperative and intraoperativ... 18607816 - Hormonal carcinogenesis and socio-biological development factors in endometrial cancer:... 11392026 - Regulating menstrual bleeding. a prime function of progesterone. 11240776 - Port site recurrences following laparoscopically managed early stage endometrial cancer. 15706506 - Kernel mixture survival models for identifying cancer subtypes, predicting patient's ca... 7940496 - Both class i and class ii hla antigens are thyroid cancer susceptibility factors. |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-09-23 |
Journal Detail:
|
Title: Endocrine-related cancer Volume: 17 ISSN: 1479-6821 ISO Abbreviation: Endocr. Relat. Cancer Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-09-27 Completed Date: 2011-01-07 Revised Date: 2011-04-20 |
Medline Journal Info:
|
Nlm Unique ID: 9436481 Medline TA: Endocr Relat Cancer Country: England |
Other Details:
|
Languages: eng Pagination: R263-71 Citation Subset: IM |
Affiliation:
|
Department of Endocrinology and Menopause, Centre for Women's Health BW, University Women's Hospital, Calwer Strasse 7, D-72076 Tuebingen, Germany. alfred.mueck@med.uni-tuebingen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Contraceptives, Oral, Hormonal
/
administration & dosage* Endometrial Neoplasms / epidemiology*, etiology Female Humans Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Contraceptives, Oral, Hormonal |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A survey of older Hong Kong people's perceptions of telecommunication technologies and telecare devi...
Next Document: European Palliative Care Research collaborative pain guidelines. Central side-effects management: wh...